Dynamic PD-L1 Regulation Shapes Tumor Immune Escape and Response to Immunotherapy.

Area of Science:

• Computational Biology
• Immunology
• Cancer Research

Background:

• Cancer immunotherapy faces challenges due to tumor cell immune escape, often involving the PD-1/PD-L1 pathway.
• Understanding adaptive resistance mechanisms is crucial for improving combination therapy efficacy.

Purpose of the Study:

• To develop and validate a mechanistic mathematical model for combination immunotherapy (Avelumab + NHS-muIL12).
• To investigate the role of dynamic PD-L1 expression in mediating therapeutic synergy and treatment failure.

Main Methods:

• Adapted an ordinary differential equation model to incorporate Avelumab and NHS-muIL12 dynamics.
• Treated PD-L1 tumor expression as a dynamic variable (ϵ) regulated by therapy.
• Validated the model using independent EMT-6 and MC38 cancer datasets.

Main Results:

• The model successfully reproduced distinct outcomes in different cancer datasets by adjusting tumor-specific parameters and PD-L1 dynamics.
• Dynamic PD-L1 upregulation following NHS-muIL12 treatment was identified as a key mechanism for tumor resistance.
• PD-1/PD-L1 blockade in combination therapy was shown to facilitate effective anti-tumor immune responses.

Conclusions:

• A validated mechanistic framework for adaptive resistance in combination immunotherapy was established.
• Quantified differences between responder and non-responder phenotypes can inform predictive tool development.
• This framework supports optimizing cancer treatment strategies by understanding immune escape dynamics.